Literature DB >> 22936422

What's all the fuss about? facts and figures about bone marrow failure and conditions.

Sudipto Mukherjee1, Mikkael A Sekeres.   

Abstract

The epidemiology of bone marrow failure conditions is not well understood. Although several population-based studies conducted in the last two decades have generated a wealth of information, it is still very challenging to interpret disease incidence and prevalence, particularly due to changes in disease classification, misdiagnosis of patients, frequent underreporting and use of different referent populations to calculate rates. Despite these limitations, the available epidemiologic data have revealed significant ethnic, geographic and clinical differences in disease biology that have implications for prevention and treatment strategies. With advances made in targeted therapies facilitated by identification of molecular biomarkers and increased use of curative bone marrow transplantation approach, the natural history of these disease entities is already changing. The epidemiology of these diseases seems to be the next frontier as knowledge gained about the risk factors and pathobiologic correlates could significantly help in designing patient-specific therapies with improved outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22936422     DOI: 10.1007/s11899-012-0134-1

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  82 in total

1.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

2.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology.

Authors:  G Socié; J Y Mary; A de Gramont; B Rio; M Leporrier; C Rose; P Heudier; H Rochant; J Y Cahn; E Gluckman
Journal:  Lancet       Date:  1996-08-31       Impact factor: 79.321

3.  Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation.

Authors:  D W Milligan; M C Ruiz De Elvira; H J Kolb; A H Goldstone; G Meloni; A Z Rohatiner; P Colombat; N Schmitz
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

4.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

5.  Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries.

Authors:  B Chen; W-L Zhao; J Jin; Y-Q Xue; X Cheng; X-T Chen; J Cui; Z-M Chen; Q Cao; G Yang; Y Yao; H-L Xia; J-H Tong; J-M Li; J Chen; S-M Xiong; Z-X Shen; S Waxman; Z Chen; S-J Chen
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

6.  Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare.

Authors:  S Oguma; Y Yoshida; H Uchino; T Maekawa; T Nomura; H Mizoguchi
Journal:  Leuk Res       Date:  1995-03       Impact factor: 3.156

7.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

Authors:  Philip S Rosenberg; Blanche P Alter; Audrey A Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Carol Fier; Melvin Freedman; George Kannourakis; Sally Kinsey; Beate Schwinzer; Connie Zeidler; Karl Welte; David C Dale
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

8.  Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure.

Authors:  Chiharu Sugimori; Kanako Mochizuki; Zhirong Qi; Naomi Sugimori; Ken Ishiyama; Yukio Kondo; Hirohito Yamazaki; Akiyoshi Takami; Hirokazu Okumura; Shinji Nakao
Journal:  Br J Haematol       Date:  2009-07-28       Impact factor: 6.998

9.  Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

Authors:  Hongbo Wang; Tatsuya Chuhjo; Shizuka Yasue; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens.

Authors:  L Ingram; M G Mott; J R Mann; F Raafat; P J Darbyshire; P H Morris Jones
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

View more
  2 in total

Review 1.  Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

Review 2.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.